Screening for AL Amyloidosis in Smoldering Multiple Myeloma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Screening for AL Amyloidosis in Smoldering Multiple Myeloma	Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, hematologic disorder, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, proteostasis deficiencies, smoldering plasma cell myeloma	Recruiting	Not stated	2025-08-06		NCT06365060

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute (NCI)	3015
Tufts Medical Center	50

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Atrium Health Levine Cancer Institute	Charlotte	United States	14
Cedars-Sinai Medical Center	Los Angeles	United States	392
Cleveland Clinic Florida, Weston Hospital	Weston	United States	2
Columbia University Irving Medical Center	New York	United States	234
Memorial Sloan Kettering Cancer Center	New York	United States	1000
The Ohio State University Comprehensive Cancer Center	Columbus	United States	29
Tufts Medical Center	Boston	United States	238
UNC Lineberger Comprehensive Cancer Center	Durham	United States	1
University of Alabama Hospital	Birmingham	United States	10
University of California, San Francisco	San Francisco	United States	294
University of Utah, Huntsman Cancer Hospital	Salt Lake City	United States	2
UT Southwestern, Harold C. Simmons Comprehensive Cancer Center	Dallas	United States	1
VCU Medical Center	Richmond	United States	5